Clearmind Advances CMND-100 Trial with Third Cohort Enrollment

Event summary

  • Clearmind Medicine has begun enrolling participants for the third cohort of its Phase I/IIa trial for CMND-100, a non-hallucinogenic treatment for Alcohol Use Disorder (AUD).
  • The trial is being conducted at Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center following positive topline results from the second cohort.
  • The Data and Safety Monitoring Board (DSMB) has unanimously approved the continuation of the trial.

The big picture

Clearmind’s advancement in its Phase I/IIa trial reflects growing confidence in CMND-100 as a potential breakthrough therapy for Alcohol Use Disorder. The inclusion of prestigious institutions like Yale and Johns Hopkins underscores the credibility of the trial, while the non-hallucinogenic nature of CMND-100 positions it uniquely in the psychedelic-derived therapeutics space. If successful, this could reshape treatment options for AUD, addressing a critical unmet need in mental health.

What we're watching

Trial Momentum
The pace at which Clearmind can complete enrollment and report results from the third cohort will indicate the trial's overall progress.
Regulatory Pathway
Whether CMND-100’s non-hallucinogenic profile will facilitate smoother regulatory approval compared to traditional psychedelic-based therapies.
Market Differentiation
How Clearmind positions CMND-100 against existing and emerging treatments for AUD, particularly those requiring adjunct psychotherapy.

Related topics

Pharmaceuticals